Arash Alizadeh, MD
Medical Oncology · Stanford, CANPI 1295824423
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $38,830 of the $46,233 with a category attached, or 84.0%. 10 manufacturers reported payments, led by Gilead at 34.4% of the total. Reporting peaked in 2019 at $24,415 and has fallen 75.8% since, to $5,903 in 2025.
Across 39 payments — averaging $1185.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$16K
- Genentech, Inc.$10K
- Adaptive Biotechnologies Corporation$8K
- AstraZeneca$6K
- Bristol Myers Squibb$4K
- Roche Sequencing Solutions, Inc.$2K
- plus $2K from 4 others
What the payments were for
- Consulting fees$38,83084%
- Speaking & faculty fees$3,3597%
- Travel & lodging$3,2007%
- Food & beverage$8292%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 15 | $15,907 |
| Genentech, Inc. | 7 | $9,564 |
| Adaptive Biotechnologies Corporation | 2 | $8,400 |
| AstraZeneca | 6 | $5,533 |
| Bristol Myers Squibb | 1 | $3,750 |
| Roche Sequencing Solutions, Inc. | 1 | $1,500 |
| Karyopharm Therapeutics Inc. | 1 | $1,180 |
| Taiho Oncology, Inc. | 4 | $370 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $16 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- clonoSEQ$8,400
- Inrebic$3,750
- SEQUENCING RESEARCH & DEVELOPMENT$1,500
- XPOVIO$1,180
How this compares
$46,233 in reported general payments places this provider in the 75th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Mark PegramStanford$374K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Gabriel MannisStanford$171K
- Lipika GoyalStanford$166K
- Melinda TelliStanford$137K
- Ranjana AdvaniStanford$113K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.